Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer
Trial Details
- NCT ID
- NCT04616209
- Phase
- PHASE1 / PHASE2
- Sponsor
- Precision Biotech Taiwan Corp.
- Status
- RECRUITING
- Cancer Type
- Lung Cancer
- Interventions
- donor-derived NK cell infusion
- Locations (sample)
- Taipei, Taiwan|25.05306,121.52639
Key Eligibility Criteria
- Recipient:
- Recipients (Subjects) are between 20-70 years of age.
- Related donor: 6/6 matched at HLA-A, -B and -DRb1 or haploidentical donor ≥ 4/8 match at HLA-A, -B, -C and -DRb1
- Signed informed consent.
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →